Gastrointestinal Oncology
Study team
Studies
Download as Excel23 studies
CODEBREAK 301Colon · mCRCColon · mCRCOpen for participation
- Tumour type
- mCRC
- Mutation / biomarker
- KRAS p.G12C
- Therapy lines
- First line
- Treatment
- Sotorasib (AMG 510) + Panitumumab+ Folfiri vs Investigators choice (Folfox or Folfiri + bevacizumab-awwb)
- Register
- NCT06252649
- Source
- Tab DARM · row 4
Original data
Tumortype: mCRC
Mutatie: KRAS p.G12C
1e lijn: CODEBREAK 301
Status: OPEN
Register: NCT06252649
Behandeling: Sotorasib (AMG 510) + Panitumumab+ Folfiri vs Investigators choice (Folfox or Folfiri + bevacizumab-awwb)
222892/AZUR-4Colon · ColonCaColon · ColonCaOpen for participation
- Tumour type
- ColonCa
- Mutation / biomarker
- MMRp/MSS
- Therapy lines
- Neoadjuvant, Adjuvant
- Treatment
- Dostarlimab + Capeox vs Capeox alone followed by surgery
- Register
- NCT06567782
- Source
- Tab DARM · row 6
Original data
Tumortype: ColonCa
Mutatie: MMRp/MSS
Neo-Adjuvant: 222892/AZUR-4
Adjuvant: 222892/AZUR-4
Status: OPEN
Register: NCT06567782
Behandeling: Dostarlimab + Capeox vs Capeox alone followed by surgery
C6461003 / Symbiotic-GI-03Colon · mCRCColon · mCRCOpen for participation
- Tumour type
- mCRC
- Mutation / biomarker
- MSS
- Therapy lines
- First line
- Treatment
- An interventional, phase 3, double-blind, randomized study to evaluate the efficacy and safety of pf-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer
- Source
- Tab DARM · row 9
Original data
Tumortype: mCRC
Mutatie: MSS
1e lijn: C6461003 / Symbiotic-GI-03
Behandeling: An interventional, phase 3, double-blind, randomized study to evaluate the efficacy and safety of pf-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer
M24-560Colon · mCRCColon · mCRCOpen for participation
- Tumour type
- mCRC
- Therapy lines
- Third line
- Treatment
- An open-label, Randomized, controlled, global phase 3 study comparing Telisotuzumab Adizutecan (AVVV-400) + Bevacizumab to LONSURF + Bevacizumab in subjecs with refractory metastatic colorectal cancer
- Source
- Tab DARM · row 10
Original data
Tumortype: mCRC
3e lijn: M24-560
Status: OPEN
Behandeling: An open-label, Randomized, controlled, global phase 3 study comparing Telisotuzumab Adizutecan (AVVV-400) + Bevacizumab to LONSURF + Bevacizumab in subjects with refractory metastatic colorectal cancer
RAINSPOTOesophagus · GEAOesophagus · GEAOpen for participation
- Tumour type
- GEA
- Mutation / biomarker
- CLDN18.2 positief
- Therapy lines
- Second line
- Treatment
- Paclitaxel-Ramucirumab-Zolbetuximab
- Source
- Tab SLOKDARM · row 3
Original data
Tumortype: GEA
Mutatie: CLDN18.2 positief
2e lijn: RAINSPOT
Status: OPEN
Behandeling: Paclitaxel-Ramucirumab-Zolbetuximab
RAINSPOTStomach · GEAStomach · GEAOpen for participation
- Tumour type
- GEA
- Mutation / biomarker
- CLDN18.2 positief
- Therapy lines
- Second line
- Treatment
- Paclitaxel-Ramucirumab-Zolbetuximab
- Source
- Tab MAAG · row 3
Original data
Tumortype: GEA
Mutatie: CLDN18.2 positief
2e lijn: RAINSPOT
Status: OPEN
Behandeling: Paclitaxel-Ramucirumab-Zolbetuximab
STEREOPACPancreas · Pancreatic Adenocarcinoma (Borderline resectable)Pancreas · Pancreatic Adenocarcinoma (Borderline resectable)Open for participation
- Tumour type
- Pancreatic Adenocarcinoma (Borderline resectable)
- Therapy lines
- Neoadjuvant
- Treatment
- Neo-adjuvant mFFX (or Gem-NabP) vs neo-adjuvant mFFX + preop SBRT
- Register
- NCT05083247
- Source
- Tab PANCREAS · row 2
Original data
Tumortype: Pancreatic Adenocarcinoma (Borderline resectable)
Neo-Adjuvant: STEREOPAC
Status: OPEN
Register: NCT05083247
Behandeling: Neo-adjuvant mFFX (or Gem-NabP) vs neo-adjuvant mFFX + preop SBRT
TORPEDOPancreas · Inoperable non-metastasized Pancreatic AdenocarcinomaPancreas · Inoperable non-metastasized Pancreatic AdenocarcinomaOpen for participation
- Tumour type
- Inoperable non-metastasized Pancreatic Adenocarcinoma
- Therapy lines
- First line
- Treatment
- Induction Folfirinox of Gem/Abraxane + restaging: Indien CR of respons randomisatie (1:1) naar 1 maand chemo gevolgd door SBRT vs 1 maand chemo alleen
- Source
- Tab PANCREAS · row 3
Original data
Tumortype: Inoperable non-metastasized Pancreatic Adenocarcinoma
1e lijn: TORPEDO
Status: OPEN
Register: NA
Behandeling: Induction Folfirinox of Gem/Abraxane + restaging: Indien CR of respons randomisatie (1:1) naar 1 maand chemo gevolgd door SBRT vs 1 maand chemo alleen
DESTINY-BTC01Gallbladder and bile ducts · locally advanced or metastatic BCT HER+Gallbladder and bile ducts · locally advanced or metastatic BCT HER+Open for participation
- Tumour type
- locally advanced or metastatic BCT HER+
- Mutation / biomarker
- HER2+
- Therapy lines
- First line
- Treatment
- Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig vs SOC Gemcitabine, Cisplatin & Durvalumab
- Source
- Tab GALBLAAS · row 2
Original data
Tumortype: locally advanced or metastatic BCT HER+
Mutatie: HER2+
1e lijn: DESTINY-BTC01
Status: OPEN
Behandeling: Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig vs SOC Gemcitabine, Cisplatin & Durvalumab
ARTEMIDE-Biliary2Gallbladder and bile ducts · Locally advanced or metastatic BTCGallbladder and bile ducts · Locally advanced or metastatic BTCOpen for participation
- Tumour type
- Locally advanced or metastatic BTC
- Therapy lines
- First line
- Treatment
- Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With
- Source
- Tab GALBLAAS · row 3
Original data
Tumortype: Locally advanced or metastatic BTC
1e lijn: ARTEMIDE-Biliary2
Status: OPEN
Behandeling: Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With
SAUNANeuroendocrine tumours · GEP NETNeuroendocrine tumours · GEP NETOpen for participation
- Tumour type
- GEP NET
- Therapy lines
- Second line
- Treatment
- continuing somatostatin analogues upon progression in NET patients
- Register
- NCT05701241
- Source
- Tab NET · row 4
Original data
Tumortype: GEP NET
2e lijn: SAUNA
Status: OPEN
Register: NCT05701241
Behandeling: continuing somatostatin analogues upon progression in NET patients
ROSETTAColon · mCRCColon · mCRCTemporarily paused
- Tumour type
- mCRC
- Mutation / biomarker
- MSS
- Therapy lines
- First line
- Treatment
- : A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Source
- Tab DARM · row 8
Original data
Tumortype: mCRC
Mutatie: MSS
1e lijn: ROSETTA
Status: ON HOLD
Behandeling: : A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
B7H3Colon · unresectable locally advanced or unresectable metastatic CRCColon · unresectable locally advanced or unresectable metastatic CRCTemporarily paused
- Tumour type
- unresectable locally advanced or unresectable metastatic CRC
- Therapy lines
- Second line, Third line
- Treatment
- A Phase1b/2, multicenter, randomized, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors
- Source
- Tab DARM · row 11
Original data
Tumortype: unresectable locally advanced or unresectable metastatic CRC
2e lijn: B7H3
3e lijn: B7H3
Status: On Hold
Behandeling: A Phase1b/2, multicenter, randomized, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors
B7H3Pancreas · eerder behandelde, gevorderde, niet-resectabele of gemetastaseerde gastro-intestinale solide tumorenPancreas · eerder behandelde, gevorderde, niet-resectabele of gemetastaseerde gastro-intestinale solide tumorenTemporarily paused
- Tumour type
- eerder behandelde, gevorderde, niet-resectabele of gemetastaseerde gastro-intestinale solide tumoren
- Therapy lines
- Second line
- Treatment
- Een fase 1b/2, multicentrische, open-label studie naar de werkzaamheid en veiligheid van GSK5764227, zowel alleen als in combinatie gegeven, bij deelnemers met eerder behandelde, gevorderde, niet-resectabele of gemetastaseerde gastro-intestinale solide tumoren.
- Source
- Tab PANCREAS · row 4
Original data
Tumortype: eerder behandelde, gevorderde, niet-resectabele of gemetastaseerde gastro-intestinale solide tumoren
2e lijn: B7H3
Status: On hold
Behandeling: Een fase 1b/2, multicentrische, open-label studie naar de werkzaamheid en veiligheid van GSK5764227, zowel alleen als in combinatie gegeven, bij deelnemers met eerder behandelde, gevorderde, niet-resectabele of gemetastaseerde gastro-intestinale solide tumoren.
DNETNeuroendocrine tumours · DNETNeuroendocrine tumours · DNETTemporarily paused
- Tumour type
- DNET
- Therapy lines
- Observation / registry
- Treatment
- Data collectie
- Source
- Tab NET · row 2
Original data
Tumortype: DNET
Observatie/registratie: DNET
Status: ON HOLD
Register: NA
Behandeling: Data collectie
BNT122-01Colon · CRCColon · CRCClosed
- Tumour type
- CRC
- Therapy lines
- Adjuvant
- Treatment
- RO7198457 vs watchful waiting
- Register
- NCT04486378
- Source
- Tab DARM · row 2
Original data
Tumortype: CRC
Adjuvant: BNT122-01
Status: STOP INCLUSIE
Register: NCT04486378
Behandeling: RO7198457 vs watchful waiting
MK1308A-008 (cohort B)Colon · mCRCColon · mCRCClosed
- Tumour type
- mCRC
- Mutation / biomarker
- dMMR/MSI-H
- Therapy lines
- First line
- Treatment
- Pembro mono vs pembro combinatie
- Register
- NCT04895722
- Source
- Tab DARM · row 3
Original data
Tumortype: mCRC
Mutatie: dMMR/MSI-H
1e lijn: MK1308A-008 (cohort B)
Status: STOP INCLUSIE
Register: NCT04895722
Behandeling: Pembro mono vs pembro combinatie
219606/AZUR-2Colon · ColonCaColon · ColonCaClosed
- Tumour type
- ColonCa
- Mutation / biomarker
- dMMR/MSI-H
- Therapy lines
- Neoadjuvant, Adjuvant
- Treatment
- Dostarlimab followed by surgery, followed by Dostarlimib vs Surgery followed by SOC (chemo or watch and wait)
- Register
- NCT05855200
- Source
- Tab DARM · row 5
Original data
Tumortype: ColonCa
Mutatie: dMMR/MSI-H
Neo-Adjuvant: 219606/AZUR-2
Adjuvant: 219606/AZUR-2
Status: closed
Register: NCT05855200
Behandeling: Dostarlimab followed by surgery, followed by Dostarlimab vs Surgery followed by SOC (chemo or watch and wait)
M24-311Colon · mCRCColon · mCRCClosed
- Tumour type
- mCRC
- Mutation / biomarker
- MSS or pMMR, BRAFV600E wt
- Therapy lines
- Second line
- Treatment
- ABBV-400 + 5FU, folinic acid and Bevacizumab vs SOC Folfiri + Beva (Q2w)
- Register
- NCT06107413
- Source
- Tab DARM · row 7
Original data
Tumortype: mCRC
Mutatie: MSS or pMMR, BRAFV600E wt
2e lijn: M24-311
Status: STOP INCLUSIE
Register: NCT06107413
Behandeling: ABBV-400 + 5FU, folinic acid and Bevacizumab vs SOC Folfiri + Beva (Q2w)
MK3475-975Oesophagus · ESCC/GEJ/EACOesophagus · ESCC/GEJ/EACClosed
- Tumour type
- ESCC/GEJ/EAC
- Therapy lines
- First line
- Treatment
- dCRT + Folfox + Pembrolizumab/Placebo
- Register
- NCT04210115
- Source
- Tab SLOKDARM · row 2
Original data
Tumortype: ESCC/GEJ/EAC
1e lijn: MK3475-975
Status: STOP INCLUSIE
Register: NCT04210115
Behandeling: dCRT + Folfox + Pembrolizumab/Placebo
MK2870-015Stomach · Advanced/metatstatic gastric, GEJ, EACStomach · Advanced/metatstatic gastric, GEJ, EACClosed
- Tumour type
- Advanced/metatstatic gastric, GEJ, EAC
- Therapy lines
- Third line
- Treatment
- MK-2870 (TROP2) ADC versus Treatment of Physician’s Choice
- Source
- Tab MAAG · row 2
Original data
Tumortype: Advanced/metastatic gastric, GEJ, EAC
3e lijn: MK2870-015
Status: STOP inclusie
Register: NA
Behandeling: MK-2870 (TROP2) ADC versus Treatment of Physician’s Choice
RYZ101-301Neuroendocrine tumours · GEP NETNeuroendocrine tumours · GEP NETClosed
- Tumour type
- GEP NET
- Therapy lines
- Second line
- Treatment
- RYZ101 (actinium Ac 225 dotatate injection) vs SOC na progressie op eerdere behandeling met 177Lu-DOTATATE/TOC
- Register
- NCT05477576
- Source
- Tab NET · row 3
Original data
Tumortype: GEP NET
2e lijn: RYZ101-301
Status: STOP inclusie
Register: NCT05477576
Behandeling: RYZ101 (actinium Ac 225 dotatate injection) vs SOC na progressie op eerdere behandeling met 177Lu-DOTATATE/TOC
BALLADSmall bowelSmall bowelClosed
- Therapy lines
- First line
- Treatment
- Group 1: adjuvant chemotherapy versus observation Group 2: monotherapy (5-FU/FA or capecitabin) versus combined therapy (5FU/FA orcapecitabin +oxaliplatin)
- Register
- NCT04257461
- Source
- Tab DUNNE DARM · row 2
Original data
1e lijn: BALLAD
Status: STOP INCLUSIE
Register: NCT04257461
Behandeling: Group 1: adjuvant chemotherapy versus observation Group 2: monotherapy (5-FU/FA or capecitabin) versus combined therapy (5FU/FA or capecitabin +oxaliplatin)